Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain

NCT01129960 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT01129960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2010
Completion date
April 30, 2012
Enrollment
332 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

painful diabetic neuropathy